KRAS and lung adenocarcinoma: Loss of LKB1 frequently occurs in KRAS-driven lung adenocarcinoma, and has been shown to promote metastasis, shorten overall survival, and confer resistance to targeted therapies and checkpoint inhibitors6–10.